Cancer

Cover image for Vol. 121 Issue 15

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.889

ISI Journal Citation Reports © Ranking: 2014: 32/211 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

Highlighted Papers

  • Does one size fit all? The updated ovarian cancer staging: Still a work in progress

    Does one size fit all? The updated ovarian cancer staging: Still a work in progress

    View (×20) showing the transition from normal tubal epithelium (Top) to a serous tubal intraepithelial carcinoma (Bottom).

  • A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

    A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

    Two patients with relapsed diffuse large B-cell lymphoma achieved complete remission with temsirolimus plus bortezomib on protocol.

  • Ovarian cancer treatment: The end of empiricism?

    Ovarian cancer treatment: The end of empiricism?

    Current treatment strategy in ovarian cancer

  • Immunotherapy in acute myeloid leukemia

    Immunotherapy in acute myeloid leukemia

    Immunotherapeutic approaches to acute myelogenous leukemia (AML).

  • Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

    Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma

    (A) Clear cell renal cell carcinoma with sarcomatoid differentiation and (B) clear cell renal cell carcinoma without sarcomatoid differentiation.

  • Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery

    Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery

    Heat shock protein 60 (Hsp60) in tumor tissues.

  • Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases

    Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases

    The study design for identifying very small nuclear circulating tumor cells (vsnCTCs) in patients with prostate cancer (PC).

  • Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry

    Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry

    Schematic of immunomagnetic enrichment coupled with flow cytometry for the detection and isolation of circulating tumor cells.

  • Does one size fit all? The updated ovarian cancer staging: Still a work in progress
  • A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study
  • Ovarian cancer treatment: The end of empiricism?
  • Immunotherapy in acute myeloid leukemia
  • Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma
  • Heat shock protein 60 levels in tissue and circulating exosomes in human large bowel cancer before and after ablative surgery
  • Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases
  • Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry

SEARCH

SEARCH BY CITATION